Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04056026
Recruitment Status : Completed
First Posted : August 14, 2019
Last Update Posted : September 23, 2019
Sponsor:
Information provided by (Responsible Party):
ProgenaBiome

Brief Summary:
The investigators propose to ensure a favorable gut microbiome by fecal microbiota transplant to enhance the efficacy Keytruda

Condition or disease Intervention/treatment Phase
Mesothelioma Biological: Fecal Microbiota Transplant Early Phase 1

Detailed Description:
Studies have shown that a favorable microbiome can be the difference between response and non-response of certain cancer treatments such as PD-1 blockade inhibitors. As such the investigators propose to ensure a favorable microbiome in this patient by fecal microbiota transplant to enhance the efficacy of such a drug, Keytruda.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Dose FMT Infusion From a Healthy Family Donor Via Colonoscopy as an Adjunct to Keytruda for the Benefit of Improving Efficacy of Immunotherapy for Metastatic Mesothelioma
Actual Study Start Date : September 18, 2018
Actual Primary Completion Date : December 18, 2018
Actual Study Completion Date : December 18, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Fecal Microbiota Transplant
The patient will undergo fecal microbiota transplant. The 600cc of donor stool will be transplanted by colonoscopy.
Biological: Fecal Microbiota Transplant
Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
Other Name: FMT




Primary Outcome Measures :
  1. Progression free survival [ Time Frame: Five years ]
    The time from transplant that the patient's tumors remain stable or shrink.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient with metastatic mesothelioma deemed a candidate for PD-1 blockade inhibitor therapy

Exclusion Criteria:

  • Patient unable/unwilling to comply with protocol
  • Patient deemed not a candidate for PD-1 Blockade inhibitor therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04056026


Locations
Layout table for location information
United States, California
ProgenaBiome
Ventura, California, United States, 93003
Sponsors and Collaborators
ProgenaBiome

Additional Information:
Layout table for additonal information
Responsible Party: ProgenaBiome
ClinicalTrials.gov Identifier: NCT04056026     History of Changes
Other Study ID Numbers: ProgenaBiome-001
First Posted: August 14, 2019    Key Record Dates
Last Update Posted: September 23, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents